TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02237859
Drug: Vancomycin
Normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vancomycin Group: Study participants started on a broad-spectrum antibiotic will be initiated on Vancomycin 125 mg PO QD within 48 hrs of the 1st dose of primary broad-spectrum antibiotic and continued to complete a 10 day course regardless of the duration of primary antibiotic. Dose of oral Vancomycin is 125 mg PO QD. Vancomycin liquid will be dissolved in fruit juice which is standard practice at Spectrum Health Hospitals. Both groups will continue in the study even if their broad spectrum antibiotic therapy is curtailed prior to 10 days.
Study: NCT00541073
Drug: cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00541073
Drug: pemetrexed disodium
Normalized name: Pemetrexed Disodium
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT02360956
Drug: Olmesartan medoxomil tablets
Normalized name: Olmesartan Medoxomil Tablets
DrugBank: Olmesartan (DB00275)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dosage must be individualized. The usual recommended starting dose of Benicar is 20mg once daily when used as monotherapy in patients who are not volume-contracted.For patients requiring further reduction in blood pressure after 2 weeks of therapy, the dose of Benicar may be increased to 40 mg. Doses above 40 mg do not appear to have greater effect. Twice-daily dosing offers no advantage over the same total dose given once daily.
Study: NCT03637816
Drug: Anamorelin Hydrochloride
Normalized name: Chlorpromazine Hydrochloride
DrugBank: Anamorelin (DB06645)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Given PO
Study: NCT00047840
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04115293
Drug: zilucoplan (RA101495)
Normalized name: Zilucoplan
DrugBank: Zilucoplan (DB15636)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily subcutaneous (SC) injection
Study: NCT00144976
Drug: Tarceva
Normalized name: Tarceva
DrugBank: Erlotinib (DB00530)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tarceva will be administered at dosage 150 mg od one hour before or two hours after meat. Patients will receive Tarceva between 18 and 28 days.
Study: NCT02282670
Drug: DA-5204
Normalized name: DAS-181
DrugBank: DAS-181 (DB15313)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01110707
Drug: Recombinant human follicle stimulating hormone (r-hFSH)
Normalized name: Recombinant human follicle stimulating hormone beta
DrugBank: Follitropin (DB00066)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Subjects will receive subcutaneous injection of recombinant human follicular stimulating hormone (r-hFSH) 300-450 International Units (IU) administered after pituitary desensitization according to the ovarian response with gonadotrophin-releasing hormone agonist (GnRH-a; at a dose of 0.1 milligram per day \[mg/day\]).
Study: NCT01110707
Drug: Recombinant human luteinizing hormone (r-hLH)
DrugBank: Lutein (DB00137)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects will receive subcutaneous injection of recombinant human luteinizing hormone (r-hLH) 150 IU/day until the end of ovarian stimulation.
Study: NCT04245865
Drug: Calcium folinate
Normalized name: Calcium folinate
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 400 mg/m2 iv
Study: NCT04245865
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 85 mg/m2 iv
Study: NCT04245865
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 5 mg/kg OR 7.5 mg/kg iv
Study: NCT04603287
Drug: SI-B001
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration by intravenous infusion.
Study: NCT01303887
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab 375mg/m2 IV day 1,repeated every 21 days for 8 cycles. All patients who have achieved a CR or PR to induction therapy will receive rituximab maintenance (375mg/m2 every 2 months for 2 years).
Study: NCT04101331
Drug: AFM13
Normalized name: AFM13 (ANTI CD30 X ANTI CD16)
DrugBank: Acimtamig (DB18674)
Approvals — FDA: no, EMA: no, PMDA: no
Description: weekly intravenous infusions of 200mg
Study: NCT01303887
Drug: Vincristine
Normalized name: Vincristine
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vincristine 1.4mg/m2 IV day 1,repeated every 21 days for 8 cycles.
Study: NCT01303887
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fludarabine 40mg/m2 PO day 1-3,repeated every 21 days for 4 cycles
Study: NCT04400474
Drug: Cabozantinib 40 mg
Normalized name: cabozantinib 40 MG
DrugBank: Cabozantinib (DB08875)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: All the subjects will be treated with the combination of cabozantinib and atezolizumab until disease progression, unacceptable toxicity or patient consent withdrawal (whichever occurs first).
Study: NCT03032666
Drug: sofosbuvir/velpatasvir
Normalized name: SOFOSBUVIR/VELPATASVIR
DrugBank: Sofosbuvir (DB08934)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: treatment of hepatitis C genotype 1-6 in patients with transfusion-dependent thalassemia.
Study: NCT01189214
Drug: Memantine
Normalized name: Memantine
DrugBank: Memantine (DB01043)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Add-on of memantine or placebo treatment will proceed in a double-blinded fashion for 12 weeks after adjusted methadone dose. During the study, we will evaluate treatment response and adverse effect from multiple dimensions to elucidate the therapeutic effect of add-on memantine on addictive behaviors. It will also explore the possible advantage of this treatment on social re-adaptation and psychopathogenesis of opioid dependence.
Study: NCT00687765
Drug: bsi-201 plus temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: BSI-201 given iv. 2x weekly, temozolomide given orally
Study: NCT03165500
Drug: Diazepam
Normalized name: Diazepam
DrugBank: Diazepam (DB00829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients' vital signs (blood pressure, heart rate and oxygen saturation) were measured and recorded after 30 minutes of oral sedation with diazepam 5mg, during the extraction procedure and 15 minutes after the extraction.~After the surgical procedure of extraction, the patients remained in recovery in the same room, being the criteria of discharge realized, from the normality of the vital signs and the response to the verbal commands, with the patient responsive and lucid.
Study: NCT04464122
Drug: Somatostatin analog; chemotherapy
DrugBank: Somatostatin (DB09099)
Approvals — FDA: no, EMA: no, PMDA: no
Description: According to current ENETS guidelines, patients will be treated by somatostatin analogs or chemotherapy, recommended respectively as first line therapy in neuroendocrine tumours or neuroendocrine neoplasms.
Study: NCT03296657
Drug: stannous fluoride
Normalized name: Stannous Fluoride
DrugBank: Stannous fluoride (DB11092)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: subjects will brush with paste twice daily for 2 weeks
Study: NCT03165500
Drug: Midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients' vital signs (blood pressure, heart rate, and oxygen saturation) were measured and recorded after 30 minutes of oral sedation with midazolam 7.5mg during the extraction procedure and 15 minutes after the extraction.~After the surgical procedure of extraction, the patients remained in recovery in the same room, being the criteria of discharge realized, from the normality of the vital signs and the response to the verbal commands, with the patient responsive and lucid.
Study: NCT03165500
Drug: Nitrous Oxide + Oxygen Gas
Normalized name: nitrous oxide Gas for Inhalation
DrugBank: Nitrous oxide (DB06690)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients' vital signs (blood pressure, heart rate, and oxygen saturation) were measured and recorded after 30 minutes of sedation Inhalation with the mixture of 40% of nitrou oxide and 60% of oxygen, during the exodontia procedure and 15 minutes later.~After the surgical procedure of extraction, the patients remained in recovery in the same room, being the discharge criteria performed, from the normality of the vital signs and the response to the verbal commands, with the patient responsive and lucid, and after the accomplishment of the test developed by Trieger et al.,(1971).
Study: NCT02982850
Drug: Dabigatran
Normalized name: Dabigatran
DrugBank: Dabigatran (DB14726)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02982850
Drug: Warfarin
Normalized name: Warfarin
DrugBank: Warfarin (DB00682)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01337947
Drug: Definity microbubbles
Normalized name: AUTOLOGOUS CD4+ AND CD8+ T CELLS OBTAINED BY LEUKAPHERESIS, TRANSDUCED WITH AN HIV-DERIVED SELF-INACTIVATING (SIN) LENTIVIRAL VECTOR, ENCODING AN ENHANCED-AFFINITY T CELL RECEPTOR (TCR) SPECIFIC FOR THE HUMAN MELANOMA ANTIGEN A4 (MAGE FAMILY MEMBER A4, A
DrugBank: Afamitresgene autoleucel (DB18592)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Definity microbubbles are used as a contrast agent to image blood flow in skeletal muscle
Study: NCT00449046
Drug: GW815SF Salmeterol/Fluticasone propionate(HFA MDI)
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00499018
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 375 mg/m2 day 1
Study: NCT00499018
Drug: Ciclofosfamide
Normalized name: Ciclofosfamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1200 mg/m2 day 1
Study: NCT00499018
Drug: Doxorubicina
Normalized name: Doxorubicina
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 70 mg/m2 day 1
Study: NCT00499018
Drug: Vincristina
Normalized name: Vincristina
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1,4 mg/m2 (max 2 mg) day 1
Study: NCT00499018
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100 mg day g 1-5
Study: NCT00499018
Drug: Pegfilgrastim
Normalized name: Pegfilgrastim
DrugBank: Pegfilgrastim (DB00019)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 6 mg day +1
Study: NCT00499018
Drug: Mitoxantrone
Normalized name: Mitoxantrone
DrugBank: Mitoxantrone (DB01204)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 8 mg/m2/days 1-3
Study: NCT00499018
Drug: ARA-C
Normalized name: Ara-C
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2000 mg/m2/12h day 1 - 3
Study: NCT00499018
Drug: Lenograstim
Normalized name: LENOGRASTIM
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 μg/Kg/days +2
Study: NCT00499018
Drug: BCNU
Normalized name: BCNU
DrugBank: Carmustine (DB00262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 300 mg/m2 day -7
Study: NCT00499018
Drug: ARA-C
Normalized name: Ara-C
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 200 mg/m2/12 days -6,-5,-4,-3
Study: NCT00499018
Drug: VP-16
Normalized name: Provp-16i
DrugBank: Etoposide toniribate (DB17255)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg/m2/12h days -6,-5,-4,-3
Study: NCT00499018
Drug: Ciclofosfamide
Normalized name: Ciclofosfamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 750 mg/m2 day 1
Study: NCT00499018
Drug: Doxorubicina
Normalized name: Doxorubicina
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50 mg/m2 day 1
Study: NCT01086540
Drug: prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisone dose of 40 mg (or equivalent) by mouth administered the night before and the morning of each study drug infusion.
Study: NCT01086540
Drug: methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylprednisolone (or equivalent corticosteroid) administered intravenously 30 minutes prior to each study drug infusion.
Study: NCT01086540
Drug: diphenhydramine
Normalized name: Diphenhydramine
DrugBank: Diphenhydramine (DB01075)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Diphenhydramine 50 mg (or equivalent) administered by mouth approximately thirty to sixty minutes prior to each study drug infusion.~Dose may be repeated every four hours, as needed.
Study: NCT00439426
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 130mg/m2 iv on day 1 of each 3 week cycle
Study: NCT02015650
Drug: Cetuximab
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients in treatment group A will receive Cetuximab at a loading dose of 400 mg/m2 (administered over 120 minutes) and weekly maintenance doses of 250 mg/m2 (administered over 60 minutes) in combination with radiation therapy.
Study: NCT02404376
Drug: Exenatide
Normalized name: Exenatide
DrugBank: Exenatide (DB01276)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous administration of Exenatide
Study: NCT02065739
Drug: JNJ-42165279
Normalized name: JNJ-42165279
DrugBank: JNJ-42165279 (DB15173)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive a single 30-mg (6 mL of oral suspension) dose of JNJ-42165279 orally (by mouth) on Day 1 (Period 1) and on Day 8 (Period 2).
Study: NCT02065739
Drug: Itraconazole
Normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will receive itraconazole 200 mg (2 capsules) once a day orally on Days 4, 5, 6, 7, 8, 9, and 10 (Period 2).
Study: NCT03211858
Drug: Insulin aspart
Normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: SAR341402 100 units per milliliters (U/mL) (dose range of 1 unit to 80 units) self-administered by SC injection, immediately (within 5-10 minutes) before meal intake. Dose adjusted to achieve a 2-hour postprandial plasma glucose (PPG \<10 millimoles/liter \[mmol/L\] \[\<180 milligram/deciliter {mg/dL}\]) while avoiding hypoglycemia.
Study: NCT03211858
Drug: Insulin glargine (HOE901)
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine 100 U/mL injected QD subcutaneously consistent with the local label. Doses adjusted to achieve glycemic target for fasting, preprandial plasma glucose between 4.4 to 7.2 mmol/L (80 to 130 mg/dL) without hypoglycemia.
Study: NCT02466997
Drug: tacrolimus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: tacrolimus 0.1% ointment applied twice a day for the experimental group during 24 weeks placebo ointment applied twice a day for the control group during 24 weeks
Study: NCT03779464
Drug: S1 or Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Gemcitabine 1000 mg/m² (D1, D8, q3w) and S-1 (40 mg BID for body surface area \< 1.25 m²; 50 mg BID for body surface area of 1.25-1.5 m²; and 60 mg BID for body surface area \>1.5 m²; D1-14, q3w)
Study: NCT04986384
Drug: Atoderm SOS spray Aerosol 200ml
Normalized name: SO-101
DrugBank: SO-101 (DB05345)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A bottle of 200ml topical spray was used on the eczematous skin lesions for itch relief.
Study: NCT01337505
Drug: INNO-206
Normalized name: INNO-305
DrugBank: INNO-305 (DB06025)
Approvals — FDA: no, EMA: no, PMDA: no
Description: INNO-206 at dosages of 230, 350, and 450 mg/m2 (doxorubicin equivalents of 165, 260, and 325 mg/m2) will be administered as a 30 minute IVI on Day 1 of each cycle.
Study: NCT02115672
Drug: BL-8040
Normalized name: BL-1020
DrugBank: BL-1020 (DB05687)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BL-8040 will be added to imatinib to improve CML response.
Study: NCT00096603
Drug: Raptiva (efalizumab)
Normalized name: Raptiva
DrugBank: Efalizumab (DB00095)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00552851
Drug: pegvisomant
Normalized name: Pegvisomant
DrugBank: Pegvisomant (DB00082)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: booster dosage 80 mg once sc., than 10 mg once per day, uptitration in steps of 5 mg up to an IGF-1 level in the normal range (every 4 weeks), max. 30 mg once per day. Duration of treatment: one year
Study: NCT01025453
Drug: Temsirolimus and Sorafenib
Normalized name: Temsirolimus
DrugBank: Sorafenib (DB00398)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Treatment will be with sorafenib 200 mg orally twice a day and temsirolimus 25 mg intravenous weekly. A cycle will be equivalent to 4 weeks of treatment.
Study: NCT01475097
Drug: Iodixanol
Normalized name: Iodixanol
DrugBank: Iodixanol (DB01249)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Iodixanol 320 mg I/mL given by intra-arterial administration. Comparator agent Isovue (iopamidol) 370 mg I/mL given as intra-arterial administration.
Study: NCT02465814
Drug: Vilaprisan (BAY1002670)
Normalized name: Vilaprisan
DrugBank: Vilaprisan (DB11971)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vilaprisan 2 mg (12 weeks), Vilaprisan 2 mg (12 weeks)
Study: NCT02465814
Drug: Vilaprisan (BAY1002670)
Normalized name: Vilaprisan
DrugBank: Vilaprisan (DB11971)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (12 weeks), treatment break, Vilaprisan 2 mg (12 weeks)
Study: NCT02465814
Drug: Ulipristal
Normalized name: Ulipristal
DrugBank: Ulipristal (DB08867)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Ulipristal 5 mg (12 weeks), treatment break, Ulipristal 5 mg (12 weeks)
Study: NCT02465814
Drug: Ulipristal
Normalized name: Ulipristal
DrugBank: Ulipristal (DB08867)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Placebo (12 weeks), treatment break, Ulipristal 5 mg (12 weeks)
Study: NCT02465814
Drug: Ulipristal
Normalized name: Ulipristal
DrugBank: Ulipristal (DB08867)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Ulipristal (12 weeks), treatment break, Placebo (12 weeks)
Study: NCT02002858
Drug: Nicotine Patch
Normalized name: Nicotine Patch
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03614832
Drug: Ticagrelor 90 mg
Normalized name: ticagrelor 90 MG
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: half-dose ticagrelor treatment (90 mg loading dose, then 90 mg once daily) for 1 week.
Study: NCT03614832
Drug: Clopidogrel 150 mg
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: double standard-dose clopidogrel treatment (150 mg loading dose, then 150 mg once daily) for 1 week.
Study: NCT00216931
Drug: iloprost
Normalized name: Iloprost
DrugBank: Iloprost (DB01088)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01668199
Drug: TZP-101
Normalized name: TZP-102
DrugBank: TZP-102 (DB16129)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03449147
Drug: Gefapixant 15 mg BID
Normalized name: Gefapixant
DrugBank: Gefapixant (DB15097)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Gefapixant 15 mg tablet administered orally BID
Study: NCT03449147
Drug: Gefapixant 45 mg BID
Normalized name: Gefapixant
DrugBank: Gefapixant (DB15097)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Gefapixant 45 mg tablet administered orally BID
Study: NCT00019838
Drug: 7-hydroxystaurosporine
Normalized name: 7-Hydroxystaurosporine
DrugBank: 7-Hydroxystaurosporine (DB01933)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00019838
Drug: fludarabine phosphate
Normalized name: Fludarabine Phosphate
DrugBank: Fludarabine (DB01073)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00661180
Drug: Nexavar (Sorafenib, BAY43-9006)
Normalized name: Nexavar
DrugBank: Sorafenib (DB00398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will receive Bay 43-9006 400 mg po twice daily in a continuous, uninterrupted schedule. Treatment will continue until there is objective evidence of disease progression, or until evidence of toxicities that are unacceptable and thought to be related to study drug, which requires discontinuation of drug, or due to withdrawn patient consent.
Study: NCT03602495
Drug: Donafenib
Normalized name: DONAFENIB
DrugBank: CM-4307 (DB15414)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Donafenib 0.3g Bid orally, continuously. Dose interruptions or reductions were allowed for subjects who experienced treatment-related toxicity.
Study: NCT00803374
Drug: Ipilimumab
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Infusion, IV, 10 mg/kg, Q3 weeks for 12 weeks then Q12, 12+ weeks depending on response
Study: NCT01893450
Drug: Methimazole
Normalized name: Methimazole
DrugBank: Methimazole (DB00763)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01893450
Drug: Bromocriptine
Normalized name: Bromocriptine
DrugBank: Bromocriptine (DB01200)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01893450
Drug: Pentoxifylline
Normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00370084
Drug: Itopride
Normalized name: itopride
DrugBank: Itopride (DB04924)
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral, three times daily
Study: NCT03791060
Drug: Secukinumab
Normalized name: Secukinumab
DrugBank: Secukinumab (DB09029)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Secukinumab is selective for human IL-17A and potently neutralizes the bioactivity of this cytokine. IL-17A is the central cytokine in multiple autoimmune and inflammatory processes. It is being recognized as one of the principal pro-inflammatory cytokines in autoimmune diseases such as psoriasis, PsA and AS, uveitis and is thought to play a role in other inflammatory conditions.
Study: NCT03523585
Drug: Trastuzumab deruxtecan
Normalized name: Trastuzumab deruxtecan
DrugBank: Trastuzumab deruxtecan (DB14962)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: DS-8201a is sterile lyophilized powder reconstituted into a sterile aqueous solution (100 mg/5 mL) to be administered as intravenous (IV) dose
Study: NCT00514540
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 75 mg/m\^2 IV over 60 Minutes on Day 1 of 21 day cycle.
Study: NCT03523585
Drug: Lapatinib
Normalized name: Lapatinib
DrugBank: Lapatinib (DB01259)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Investigator's choice Standard of Care when combined with capecitabine
Study: NCT03523585
Drug: Trastuzumab
Normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Investigator's choice Standard of Care when combined with capecitabine
Study: NCT00514540
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: AUC = 5 IV Over 30 Minutes On Day 1 of 21 day cycle.
Study: NCT00514540
Drug: Etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 120 mg/m\^2 daily for 3 days of 21 day cycle.
Study: NCT00514540
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 25 mg/m\^2 for 3 days of 21 day cycle.